These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35753554)

  • 21. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
    BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
    Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
    Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease.
    Osti MF; Agolli L; Valeriani M; Reverberi C; Bracci S; Marinelli L; De Sanctis V; Cortesi E; Martelli M; De Dominicis C; Minniti G; Nicosia L
    Lung Cancer; 2018 Aug; 122():165-170. PubMed ID: 30032826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies.
    Franzese C; Francolini G; Nicosia L; Alongi F; Livi L; Scorsetti M
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):50-56. PubMed ID: 32723486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
    Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
    Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
    Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
    Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
    Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
    BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
    Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
    J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease.
    Bhattacharya IS; Woolf DK; Hughes RJ; Shah N; Harrison M; Ostler PJ; Hoskin PJ
    Br J Radiol; 2015 Apr; 88(1048):20140712. PubMed ID: 25679321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors.
    Franceschini D; Teriaca MA; Di Cristina L; Vernier V; Lo Faro L; Franzese C; Comito T; Clerici E; Bellu L; Dominici L; Spoto R; Massaro M; Navarria P; Scorsetti M
    Br J Radiol; 2023 Mar; 96(1144):20220771. PubMed ID: 36809197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overall and chemotherapy-free survival following stereotactic body radiation therapy for abdominopelvic oligometastases.
    Shahi J; Peng J; Donovan E; Vansantvoort J; Wong R; Tsakiridis T; Quan K; Parpia S; Swaminath A
    J Med Imaging Radiat Oncol; 2020 Aug; 64(4):563-569. PubMed ID: 32497405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
    Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
    PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
    Hörner-Rieber J; Bernhardt D; Blanck O; Duma M; Eich HT; Gerum S; Gkika E; Hass P; Henkenberens C; Herold HU; Hildebrandt G; Imhoff D; Kahl H; Janssen S; Jurianz K; Krempien R; Lautenschläger SF; Lohaus F; Mueller AC; Petersen C; Sackerer I; Scafa D; Schrade E; Uhlmann L; Wittig A; Guckenberger M
    Clin Lung Cancer; 2019 Nov; 20(6):e667-e677. PubMed ID: 31327644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
    Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
    Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
    Kann BH; Verma V; Stahl JM; Ross R; Dosoretz AP; Shafman TD; Gross CP; Park HS; Yu JB; Decker RH
    Radiother Oncol; 2019 May; 134():44-49. PubMed ID: 31005223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression.
    Pembroke CA; Fortin B; Kopek N
    Radiother Oncol; 2018 Jun; 127(3):493-500. PubMed ID: 29735409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease.
    Cao Y; Chen H; Sahgal A; Erler D; Badellino S; Biswas T; Dagan R; Foote MC; Louie AV; Poon I; Ricardi U; Redmond KJ
    Cancer Med; 2021 Nov; 10(22):8091-8099. PubMed ID: 34668651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.